Shares in chip maker Intel (NASDAQ:INTC) were hammered throughout 2022, with INTC stock staying on a downward trajectory during the first two months of this year. As I have discussed previously, this was due to two factors. First, the company’s poor financial performance. Second, related to some extent to the first factor, was rising concerns about softening semiconductor
Month: April 2023
Beer sales were already flat. Now a right-wing backlash against one of the leading U.S. brands is adding to the industry’s problems. As slowing craft-beer sales continue to drag on the market, a number of politicians and celebrities are boycotting Bud Light. They’re in a lather because of a sponsored partnership between the beer and
Ben Rains dives into where the stock market stands as we kick off the busy stretch of first quarter earnings season. The episode then explores two giants of key industries—Taiwan Semiconductor (TSM) and Union Pacific (UNP)—that are sitting at beaten-down levels heading into earnings that might make them attractive to long-term investors. (0:30) – Stock
Most analysts agree that the Federal Reserve will likely start to cut rates later this year, and buying stocks of companies that benefit from such a rate-cut environment is a good idea. It’s hard to say whether or not we are at the terminal rate, but I can confidently say that we are pretty close
The markets may be showing solid signs of improvement, but there are still many stocks to sell. In fact, in this environment of elevated interest rates, stocks with unrealistically high valuations are likely to come back to earth sooner rather than later. So, here are seven stocks to sell in April that are very likely to
In many ways, C3.ai (NYSE:AI) stock has been a tale of two valuations over the last year. Before artificial intelligence became the latest fad due to the public’s fascination with ChatGPT, the valuation of AI stock was quite attractive. For example, on Dec. 1, 2022, the shares were changing hands for roughly 3.9 times analysts’ current average
A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study, reducing the risk of recurrence or death by 44%, the drug makers said Sunday. About 79% of melanoma patients in a 157-person trial who were treated with Moderna’s personalized mRNA-4157 (V940) therapy in combination with Merck’s
In this article DPZ CZR TXRH COST CRWD Follow your favorite stocksCREATE FREE ACCOUNT Domino’s will roll out 800 custom-branded 2023 Chevy Bolt electric vehicles at locations across the U.S. in the coming months. Domino’s Wall Street analysts are focusing on companies that are well-positioned to navigate the ongoing economic turmoil and emerge stronger. Here
Buying dividend stocks trading at discount pricing is generally a smart idea. Such equities give owners the dual benefit of price appreciation potential in their forward-looking target prices. And two, they also provide nominal income through their periodic dividends. Provided the investor isn’t speculating in high-risk shares, it’s a reasonable strategy overall. Each of the stocks listed
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform
Troika Media Group (NASDAQ:TRKA) has been a popular meme stock so far in 2023. Even after tanking following a short squeeze in early March, TRKA stock remains up by more than 135% year-to-date. What makes shares in this marketing company stand out among meme stocks goes beyond just the fact it has been a strong performer.
Dear Quentin, I have a “first-world” problem with a twist, and I could use your advice. I recently sold my rental townhouse for $325,000. It was already paid off without any encumbrances on the property. After paying the title transfer and capital-gains taxes of 15%, I have $309,000 in cash. Question 1: What should I
Preston Pysh interviews William Casarin about a new decentralized social media platform called Nostr which could bring free speech and anti-censorship to the internet via a Twitter-like experience. IN THIS EPISODE, YOU’LL LEARN: 00:00:00 – Intro 00:00:35 – So what is Nostr? 00:02:41 – It seems like the protocol is optimized around simplicity, is that
Visit our website: https://www.zacks.com Visit our Stocktwits account: https://stocktwits.com/ZacksResearch Check out our weekly promotion: https://www.zacks.com/promo If you’re interested in our services, please check out Zacks Ultimate: https://www.zacks.com/ultimate/?adid=YOUTUBE&cid=sm-YOUTUBE
Adene Sanchez | E+ | Getty Images Company: Exelixis (EXEL) Business: Exelixis, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. They have produced four marketed pharmaceutical products, including their flagship molecule, cabozantinib. Stock Market Value: $6.3B ($19.46 per share) Activist: Farallon Capital
Li Auto (NASDAQ:LI) is one of several Chinese electric vehicle startups with a U.S. stock market listing on a major exchange. Alongside LI stock are Nio (NYSE:NIO) and Xpeng (NYSE:XPEV). U.S. investors follow all three. Yet while some looking to capitalize on EV adoption in China may want to spread their bets around, by buying
If Novavax (NASDAQ:NVAX) stock investors are looking for a shot in the arm, they’re going to be disappointed. Even Novavax’s management expressed doubts regarding the company’s ability to continue long term. Like it or not, the evidence overwhelmingly suggests that it’s not a wise move to take a share position in Novavax. Let’s face it. Covid-19
Chinese electric vehicle maker Nio (NYSE:NIO) has multiple positive catalysts, including the expected rapid growth of the Chinese EV sector and its sedans, which are quickly becoming quite popular in the huge Asian country. Moreover, the valuation of NIO stock is very low, and two reviews of its P7 luxury sedan that I found online are quite
Dear MarketWatch, I appreciate you putting my sad predicament In your column. Somehow I have failed, not taking care of myself. I have spent my money on helping my family and was never able to save anything. The two episodes of cancers took me down quite a bit. I’m 74 years old and must continue
In this article JPM MOMO LCID BLK Follow your favorite stocksCREATE FREE ACCOUNT Getty Images Check out the companies making headlines in premarket trading. JPMorgan Chase – The banking behemoth popped more than 5% after posting record revenue that surpassed analyst expectations due to higher interest rates. JPMorgan Chase reported revenue of $39.34 billion, beating
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 17
- Next Page »